| 08/08 | BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 04/08 | BEIGENE : Reports Second Quarter 2022 Financial Results - Form 8-K | PU |
| 04/08 | BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta.. | AQ |
| 04/08 | BeiGene Reports Second Quarter 2022 Financial Results | BU |
| 20/07 | BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 15/07 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 15/07 | BEIGENE : Provides Regulatory Update on the U.S. Biologics License Application (BLA) for P.. | PU |
| 14/07 | BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for .. | BU |
| 13/07 | BeiGene Appoints Chan Lee as General Counsel | BU |
| 06/07 | BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Nov.. | BU |
| 30/06 | BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis.. | PU |
| 30/06 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 30/06 | BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti.. | BU |
| 23/06 | BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for .. | PU |
| 22/06 | BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote.. | AQ |
| 21/06 | BeiGene Announces Acceptance of Supplemental Biologics License Application in China for.. | BU |
| 14/06 | BEIGENE : Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at .. | PU |
| 14/06 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 13/06 | BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets | BU |
| 13/06 | BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatmen.. | BU |
| 10/06 | BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at.. | BU |
| 10/06 | China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer | BU |
| 08/06 | BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | BU |
| 27/05 | BEIGENE : Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and G.. | PU |
| 27/05 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 26/05 | BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and .. | BU |
| 17/05 | BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi.. | BU |
| 12/05 | BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato.. | BU |
| 09/05 | BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 05/05 | BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta.. | AQ |
| 05/05 | BeiGene Reports First Quarter 2022 Financial Results | BU |
| 04/05 | BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P.. | BU |
| 29/04 | BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes.. | BU |
| 29/04 | BEIGENE : Financial Information - Form 8-K | PU |
| 28/04 | BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta.. | AQ |
| 28/04 | BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, .. | BU |
| 27/04 | BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual.. | BU |
| 27/04 | Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che.. | BU |
| 26/04 | BeiGene Introduces Global Environmental, Social, and Governance Strategy | BU |
| 25/04 | Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene | AQ |
| 21/04 | BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Can.. | BU |
| 20/04 | BEIGENE : China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamo.. | PU |
| 20/04 | BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits .. | AQ |
| 19/04 | BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis.. | BU |
| 15/04 | China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell.. | BU |
| 12/04 | BEIGENE : Announces European Medicines Agency Acceptance of Marketing Authorization Applic.. | PU |
| 12/04 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 11/04 | IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Ver.. | BU |
| 08/04 | BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors .. | BU |
| 06/04 | BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Appli.. | BU |
| 25/03 | BEIGENE : Current Report (Form 8-K) | PU |
| 25/03 | BEIGENE, LTD. : Changes in Registrant's Certifying Accountant, Other Events, Financial Sta.. | AQ |
| 17/03 | BEIGENE : China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-Hi.. | PU |
| 17/03 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 15/03 | BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA.. | BU |
| 11/03 | China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or M.. | BU |
| 03/03 | BEIGENE, LTD. : Change in Directors or Principal Officers, Financial Statements and Exhibi.. | AQ |
| 03/03 | BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Re.. | BU |
| 03/03 | BEIGENE : An announcement has just been published by the issuer in the Chinese section of .. | PU |
| 01/03 | BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference | BU |
| 28/02 | BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 25/02 | BEIGENE : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K | PU |
| 25/02 | BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta.. | AQ |
| 25/02 | BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results | BU |
| 22/02 | BEIGENE : Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zan.. | PU |
| 22/02 | BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 22/02 | BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA.. | BU |
| 22/02 | BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (za.. | BU |
| 17/02 | BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of A.. | BU |
| 16/02 | BEIGENE, LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 09/02 | BEIGENE : Initial Statement of Beneficial Ownership (Form 3) | PU |
| 08/02 | BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference | BU |
| 02/02 | BEIGENE : Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors .. | PU |
| 02/02 | BEIGENE, LTD. : Change in Directors or Principal Officers, Other Events, Financial Stateme.. | AQ |
| 01/02 | Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors | BU |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
